Trials / Completed
CompletedNCT00083252
Study of Talabostat and Cisplatin in Advanced Melanoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Point Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the antitumor activity and safety of the combination of talabostat and cisplatin in patients with metastatic melanoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | talabostat (PT-100) tablets | |
| DRUG | cisplatin |
Timeline
- First posted
- 2004-05-18
- Last updated
- 2007-06-08
Locations
13 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00083252. Inclusion in this directory is not an endorsement.